Pfizer makes organizational changes following Wyeth deal

NEW YORK Pfizer has announced the changes it will make to its organizational structure after closing its deal to acquire Wyeth.

The drug maker announced Tuesday that it will establish a “unique” research model that will use its own and Wyeth’s scientific capabilities to support nine healthcare businesses, retaining eight senior executives from Wyeth.

The PharmaTherapeutics Research Group will focus on discovering pharmaceutical drugs, led by Martin Mackay, currently head of Pfizer Global Research & Development; the BioTherapeutics Research Group will focus on biotech drugs, including vaccines, led by Wyeth Research president Mikael Dolsten. Mackay and Dolsten will serve as presidents of their respective organizations and as members of Pfizer’s executive leadership team, reporting to Pfizer chairman and CEO Jeff Kindler.

Wyeth Vaccine Research head Emilio Emini will become chief science officer vaccine research, while Wyeth head of discovery Menelas Pangalos will become Pfizer’s chief science officer neuroscience research.

“I am honored that world-class scientists like Drs. Dolsten, Emini and Pangalos will be joining the outstanding scientists at Pfizer and, as we continue our integration planning, I look forward to our welcoming many more distinguished Wyeth scientists to our organization,” Kindler said in a statement.